Catalysts / BBIO
Upcoming FDA decisions and readouts we track for BridgeBio Pharma, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for BridgeBio Pharma (BBIO, listed on Nasdaq). They cover 2 programmes: BBP-418 (Limb-girdle muscular dystrophy type 2I/R9) and Encaleret (Autosomal dominant hypocalcaemia type 1 (ADH1)).
First on the list: the PDUFA date for BBP-418 (Limb-girdle muscular dystrophy type 2I/R9), dated 27 Nov 2026. By stage, the upcoming rows are 2 PDUFA dates.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| BridgeBio Pharma BBIO · Nasdaq | BBP-418 | Limb-girdle muscular dystrophy type 2I/R9 | 27 Nov 2026 in 51d |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
| BridgeBio Pharma BBIO · Nasdaq | Encaleret | Autosomal dominant hypocalcaemia type 1 (ADH1) | 08 May 2027 in 213d |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList